[go: up one dir, main page]

MX2020008923A - Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación. - Google Patents

Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación.

Info

Publication number
MX2020008923A
MX2020008923A MX2020008923A MX2020008923A MX2020008923A MX 2020008923 A MX2020008923 A MX 2020008923A MX 2020008923 A MX2020008923 A MX 2020008923A MX 2020008923 A MX2020008923 A MX 2020008923A MX 2020008923 A MX2020008923 A MX 2020008923A
Authority
MX
Mexico
Prior art keywords
proton pump
pump inhibitors
scarring
tissue inflammation
chemoradiation
Prior art date
Application number
MX2020008923A
Other languages
English (en)
Inventor
Yohannes T Ghebre
Michell S Ludwig
Mark David Bonnen
Pavan Mukesh Jhaveri
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2020008923A publication Critical patent/MX2020008923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las modalidades de la descripción incluyen métodos y composiciones relacionadas con el tratamiento o prevención de inflamación del tejido inducida por terapia contra el cáncer, dermatitis, y/o cicatrización. En modalidades particulares uno o más inhibidores de la bomba de protones se proporcionan a un individuo antes, durante, y/o después de recibir terapia anticáncer. En algunas modalidades uno o más inhibidores de la bomba de protones se proporcionan a un individuo antes, durante y/o después de tener condiciones de salud, alergias, factores genéticos y/o exposición a uno o más irritantes.
MX2020008923A 2018-02-28 2019-02-28 Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación. MX2020008923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636284P 2018-02-28 2018-02-28
PCT/US2019/020117 WO2019169175A1 (en) 2018-02-28 2019-02-28 Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring

Publications (1)

Publication Number Publication Date
MX2020008923A true MX2020008923A (es) 2021-01-08

Family

ID=67805927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008923A MX2020008923A (es) 2018-02-28 2019-02-28 Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación.

Country Status (10)

Country Link
US (1) US20210052563A1 (es)
EP (1) EP3758703A4 (es)
JP (1) JP2021516234A (es)
CN (1) CN112312911A (es)
AU (1) AU2019228575A1 (es)
BR (1) BR112020017413A2 (es)
CA (1) CA3092453A1 (es)
MX (1) MX2020008923A (es)
SG (1) SG11202008144UA (es)
WO (1) WO2019169175A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
WO2022094602A1 (en) * 2020-10-30 2022-05-05 Baylor College Of Medicine Proton pump inhibitors for the treatment of diseases characterized by inflammation and/or collagen accumulation
CN112516140A (zh) * 2020-12-14 2021-03-19 北京京佑奇康科技有限公司 奥美拉唑减轻酪氨酸激酶抑制剂毒副作用的用途
CN121177483A (zh) * 2025-11-21 2025-12-23 南昌大学第一附属医院 Ddahⅱ促进剂在制备抗die损伤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064458A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
WO2014076092A1 (en) * 2012-11-14 2014-05-22 Boehringer Ingelheim Vetmedica Gmbh A proton pump inhibitor for use in a method of treating dermatological diseases in canine
WO2014160947A1 (en) * 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
BR112020017413A2 (pt) 2020-12-15
EP3758703A1 (en) 2021-01-06
AU2019228575A1 (en) 2020-09-17
CA3092453A1 (en) 2019-09-06
SG11202008144UA (en) 2020-09-29
WO2019169175A1 (en) 2019-09-06
JP2021516234A (ja) 2021-07-01
EP3758703A4 (en) 2022-03-09
US20210052563A1 (en) 2021-02-25
CN112312911A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
NZ784224A (en) Parp1 inhibitors
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2016025635A3 (en) Combination therapy for treating cancer
NZ700759A (en) Combination therapy for treating cancer
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX391720B (es) Terapia combinada para tratar cáncer.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX370624B (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
MX2020008923A (es) Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019013862A (es) Terapia de combinacion.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX2020001727A (es) Terapia de combinacion.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2016015161A (es) Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer